



CureDuchenne Ventures 2020 Pitch Contest | Submission Deadline: July 13, 2020!

Rewarding Rare Approaches to Treat Duchenne Muscular Dystrophy

About the Contest:

- Open to colleges, universities, biotech companies and pharma companies in the United States with researchers at all career stages
- Focusing on new Duchenne therapeutics or therapeutic targets, or technology platforms that can help overcome current limitations of Duchenne therapies in development
- Finalists will have the opportunity to pitch their idea to a panel of esteemed judges from the drug development and venture capital communities
- Email us at Pitch@CureDuchenne.org if you have any questions

The Winning Details:

- 2 Winners each receiving no-strings attached award of \$25,000 by check made out to the winning college, university, or company
- Access to a wide array of experts in Duchenne drug discovery through CureDuchenne's network
- Ongoing mentoring from CureDuchenne lead scientists Mike Kelly, PhD & Lianna Orlando, PhD

Application Process:

FIRST ROUND:		FINALIST ROUND:	
Fill out application form and upload slide deck	Finalists selected and notified	Finalists present 15 minute pitch to expert judging panel	WINNERS PUBLICLY ANNOUNCED
DEADLINE JULY 13	WEEK OF AUGUST 3RD	AUGUST 17-21	SEPTEMBER 2020



For over a decade, CureDuchenne Ventures has funded promising research that advances us toward a cure for Duchenne muscular dystrophy. For the first time, CureDuchenne is holding a competition to stimulate and support new, innovative ideas from a wide array of sources.

This competition is an opportunity for colleges, universities, and biotech and pharma companies with outstanding scientists at all career stages to pitch their latest idea and potentially be rewarded with \$25,000.

[SUBMIT YOUR PITCH](#)

[SEE OFFICIAL RULES](#)

Finalist Judges:



**Cristina Csimma,
PharmD, MHP**

Chair of Board of Directors
Caraway Therapeutics



Mitchell H. Finer, PhD

Chief Scientific Officer,
President of ElevateBio




Dave Greenwald, PhD

VP President, Business
Development
Deerfield Management




Michael G. Kelly, PhD

Chief Scientific Advisor
CureDuchenne



**Adam M. Koppel,
MD, PhD**

Managing Director
Bain Capital Life Sciences



**Walter Kowtoniuk,
PhD**

Venture Partner
Third Rock Ventures




Martin Lehr

CEO
Context Therapeutics




Eric Olson, PhD

Professor & Chairman, Department
of Molecular Biology
UT Southwestern Medical Center



Lianna Orlando, PhD

Senior Director of Research
CureDuchenne



**Kush Parmar, MD,
PhD**

Managing Partner
5AM Ventures

Two winners, Each Receiving

\$25,000



[LEARN MORE](#)

[SUBMIT YOUR PITCH](#)

[SEE OFFICIAL RULES](#)



NO PURCHASE OR PAYMENT NECESSARY TO ENTER OR WIN. VOID IN PUERTO RICO AND WHERE PROHIBITED. Entrants must be either (a) an accredited college or university in the 50 United States or District of Columbia, or (b) a biotech or pharma company based in the 50 United States or District of Columbia. See application form, submission requirements, judging criteria, and official rules at CureDuchenne.org/pitchcontest. Entries must be submitted between 12:00 PM Eastern Time on 06/08/2020 and 4:00 PM Eastern Time on 07/13/2020. The two (2) eligible entrants with the most promising ideas in Duchenne Muscular Dystrophy therapy development will each win \$25,000. Sponsor: CureDuchenne, located at 1400 Quail Street Suite 110, Newport Beach, CA 92660.